Skip to Main Content

Paper Details

The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia.
Blood Rev
17
2020
Author NameAffiliation
Jerald P RadichFred Hutchinson Cancer Research Center, University of Washington
Stephanie HaleneYale University School of Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine
  • 1 - 2

Datasets

Release 1.2